#1-85E. A New Frontier in Refractory SLE: In Vivo CAR T-Cell Therapy (New England Journal of Medicine, 2025)

Could in vivo generated CAR T-cells be the next breakthrough for refractory systemic lupus erythematosus (SLE)? This episode dives into a recent study that explores this novel therapeutic approach. The research investigates the feasibility of HN2301, a lipid nanoparticle encapsulating CD19 CAR mRNA, administered to five patients with refractory SLE. The key finding is that this therapy successfully generated functional CAR T-cells in vivo, leading to B-cell depletion and reduced disease activity, suggesting a promising new avenue for treating autoimmune diseases. However, it is crucial to note that this study is limited by its very small sample size of only five patients, and more data are needed to assess the durability of the effect and the optimal dosing schedule. For clinicians treating patients with challenging autoimmune conditions, this study offers a glimpse into a potential future therapy that could overcome the limitations of current treatments

.Citation: WANG, Qian, et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMc2509522

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original publication for details.